CaraMed’s specialised healthcare investment focus means that the nature of CaraMed’s team is unique for a venture capital firm as a majority of the partners and team are technically qualified (i.e. scientific or clinically trained).

Our diverse team includes founders, members of founding teams of healthcare start-ups, directors and executives of healthcare corporates and start-up companies, a clinician and management in hospitals/health system.

The specialised healthcare expertise in our team spans the fields of gene therapy, molecular medicine, neuroscience, pharmacology, diagnostics, biochemistry, digital health, medical devices, biotechnology, surgery and the clinical practice of medicine.

Caroline Quay

PARTNER

Caroline is an experienced healthcare industry executive with over 15 years’ experience. Caroline’s experience and roles cover strategic development, commercial advisory, commercialisation and investments in the healthcare and biotech sectors.

Caroline spent more than a decade as an executive (Global General Counsel) of Fisher & Paykel Healthcare Limited (NZX: FPH, ASX: FPH). She was also an executive (Founding General Counsel) of Aroa Biosurgery Limited (ASX: ARX).

Caroline is Chief Investment Officer at Cure Kids Ventures, NZ’s predominant seed and early stage healthcare investment fund since 2017.

Caroline started out her career as a corporate/commercial lawyer specialising in mergers and acquisitions, private equity and venture investments with two of NZ’s premier law firms.

She is an investor in various asset classes including angel/early stage investments in the healthcare sector.

Caroline was the recipient of the EY/ NZ Asian Leaders’ Scholarship for the EY Darden Programme in 2015 (University of Virginia Darden School of Business). Caroline was also a recipient of the SBC Warburg (now UBS) Scholarship in Finance. She received her Bachelor of Laws degree with Honours and Bachelor of Commerce degree in Accounting and Finance from the University of Auckland.

Caroline is a member of New Zealand Global Women and an Established Member of New Zealand Asian Leaders and Superdiverse Women.

Dr Scott W. J. McPhee

PARTNER

Scott has undertaken collaborations with leading University research groups across the US and globally to commercialize novel technologies. He also has extensive experience in licensing and transactions with a number of leading pharma companies. Scott has worked on both preclinical and clinical development of two programs acquired by Takeda (formerly Baxter) and two programs acquired by Pfizer. He has been involved in preclinical and clinical development of programs for a number of Neurological and Neurodegenerative disorders, Eye disorders, Congestive Heart Failure, and Hemophilia A & B. His roles have spanned R&D leadership, IP Portfolio Management, and M&A Management.

Prior to becoming a biotechnology executive, Scott had a successful early career in academia, first working on gene therapies in the 90’s. He had key roles supporting the landmark first viral vector gene therapy programs targeting neurodegenerative diseases, and has over 20 publications. Scott has also had success as an Angel Investor and Founder of Antipodean Ventures, with seed or early stage investments in Allbirds (2020 Valuation USD$1.7B) and Seene (acquired by Snap) among others.

Scott has a Doctorate degree in Molecular Medicine from the University of Auckland and a Masters degree in Public Health from Harvard University.

Maxine Simmons

PARTNER

Maxine is an experienced entrepreneur, company leader and director, having been actively involved in start-up and expansion stage private company development in New Zealand for more than 30 years’ experience.

Maxine is the Executive Director of Cure Kids Ventures (CKV) and was the founding Chief Executive of CKV. Since CKV’s inception in 2008, Maxine has lead investments for CKV into an impressive portfolio of companies with products and services covering medical devices, medications, diagnostics, health information and healthcare delivery systems.

She founded one of New Zealand’s first biotechnology companies, ICPbio, which grew into a significant biotechnology export business as acknowledged by the NZ Biotechnology industry in awarding her a Distinguished New Zealand Biotechnologist Award in 2000. Maxine was also awarded the Bioscience Achievement Award in 2017.

Among numerous influential roles, she has been the founding director of Industry New Zealand (now New Zealand Trade and Enterprise); a director of the Foundation for Research, Science and Technology; Director of Industrial Research Ltd prior to it becoming Callaghan Innovation; Chair of the NZ biotechnology industry organization, NZBIO and represented New Zealand on the APEC Business Advisory Council from 2010 to 2014.

Currently Maxine is on the board of the Maurice Wilkins Centre for Molecular BioDiscovery and a director of a number of private companies.

Maxine was appointed a Companion of the New Zealand Order of Merit for her services to science, particularly biotechnology.

Maxine holds a Master of Science degree in biological sciences from the University of Auckland and is a chartered member of the NZ Institute of Directors.

Dr Ken Chin

PARTNER

Ken is a Fellow of the Royal New Zealand College of General Practitioners (FRNZCGP) and has been a practising medical doctor since 1998.

He co-founded/owned several healthcare services and healthcare consultancy businesses including a large medical practice. Ken has been a consultant providing expert clinical insight in the assessment of healthcare investments and strategic advice to healthcare businesses since 2016.

He is an experienced and successful investor in various asset classes which includes angel/early stage investment, particularly in the healthcare sector.

In his early career, Ken was involved in medical research work in endocrinology (Department of Medicine, University of Auckland) and in Urology (Auckland Hospital Urology Department).

Ken received his Bachelor of Medicine and Bachelor of Surgery (MBChB) from the University of Auckland. He also earned a Post Graduate Certificate in Travel Medicine from the University of Otago. He completed his Basic Surgical Training with the Royal Australasian College of Surgeons (RACS) and was also selected as an Advanced Surgical Trainee in Urology by the RACS.

Team Members

Alistair Mascarenhas

HEALTH IT SPECIALIST

Alistair has over 20 years IT service delivery, operations and procurement experience. He has specialised in leading IT commercial and operational teams, both in New Zealand and overseas. Alistair is passionate about technology and has a keen interest in how technology can be used to deliver positive outcomes.

Alistair has spent more than 15 years working in the New Zealand Health sector. Over his time in the Health sector he has held a variety of management roles and led the National Procurement team established to manage the procurement functions for all 20 district heath boards across New Zealand.

Alistair is currently a director with ITNewcom an IT consulting firm and is also a Board member of Chnnl.

Dr Jocelyn Segedin

Ph.D Pharmacology

Jocelyn gained her PhD in pharmacology from the University of Auckland in 2004 with a research focus in platinum based chemotherapy medicines.

Prior to returning to New Zealand, Jocelyn worked for GlaxoSmithKline in the United Kingdom where she was involved in the early stage development of antibiotic compounds.

Jocelyn also has extensive experience in data analytics and data interpretation in the engineering sector.

Micaela Lewenz

Head of Investor Relations

Micaela’s experience and roles are rooted in her passion for people. Her strength is in making meaningful connections that facilitate fruitful business partnerships.

Her roles and responsibilities have included ensuring the right strategic positioning with investors, strategic partners and other stakeholders.

Micaela’s experience in Investor Relations for venture capital funds and private investor clubs include managing two successful fund raisings for a venture capital fund from a global investor base.